AbbVie (ABBV) Announces Presentation of Data from Two Elagolix Phase 3s

October 6, 2016 8:03 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

AbbVie (NYSE: ABBV) announced that new data from two replicate Phase 3 studies evaluating the efficacy and safety of Elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, in premenopausal women with endometriosis, will be presented at the upcoming 72nd American Society for Reproductive Medicine Scientific Congress & Expo (ASRM), October 15-19, in Salt Lake City. Additional data highlighting the economic and healthcare burden associated with endometriosis will also be presented.

"Endometriosis affects an estimated one in 10 women,1 and physicians and their patients are seeking alternative options to help relieve symptoms of this disease," said Rob Scott, M.D., Vice President, Development and Chief Medical Officer, AbbVie. "The data highlight the efficacy and safety profile of Elagolix in the treatment of pain associated with endometriosis, and underscore AbbVie's efforts to help address the needs of women suffering from endometriosis."

AbbVie Posters:

  • Elagolix, An Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, For The Management Of Endometriosis-Associated Pain: Safety And Efficacy Results From Two Double-Blind, Randomized, Placebo-Controlled Studies; Taylor H, et al.; Abstract #P440; Poster Session; Wednesday, October, 19, 2016; 7:00AM – 8:45AM MDT
  • Use Of Elagolix For The Management Of Endometriosis-Associated Pain: Secondary Efficacy Results From Two Randomized, Placebo-Controlled Studies : Surrey, et al.; Abstract #P434; Poster Session; Wednesday, October, 19, 2016; 7:00AM – 8:45AM MDT
  • The Effect Of Elagolix On Bone Mineral Density: Safety Results From Two Randomized, Placebo-Controlled Studies In Women With Endometriosis-Associated Pain; Archer et al.; Abstract #P455; Poster Session; Wednesday, October, 19, 2016; 7:00AM – 8:45AM MDT
  • Incremental Costs of Healthcare and Work Loss Attributed to Endometriosis in a Cohort of Commercially Insured Women; Soliman et al.; Abstract #P432; Poster Session; Wednesday, October, 19, 2016; 7:00AM – 8:45AM MDT
  • Incidence of Comorbidities Among Women with Endometriosis: A Retrospective Matched Cohort Study; Soliman et al.; Abstract # P457; Poster Session; Wednesday, October, 19, 2016; 7:00AM – 8:45AM MDT

AbbVie Oral Presentations

  • The Effect Of Elagolix On The Endometrium: Safety Results From Two Randomized, Placebo-Controlled Studies In Women With Endometriosis-Associated Pain; Diamond et al.; Abstract #O232; Oral Session; Wednesday, October, 19, 2016; 11:15AM – 12:45PM MDT
  • The Impact of Elagolix on Quality of Life in Women with Endometriosis-Associated Pain: Results From Two Randomized, Placebo-Controlled Studies Using the Endometriosis Health Profile Questionnaire; Taylor H et al.; Abstract #O229; Oral Session; Wednesday, October, 19, 2016; 11:15AM – 12:45PM MDT
  • Direct and Indirect Costs Associated with Endometriosis-Related Surgery Among Employed Women in the US; Soliman et al.; Abstract #O230; Oral Session; Wednesday, October, 19, 2016; 11:15AM – 12:45PM MDT


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA, Management Comments

Related Entities

Twitter

Add Your Comment